Venaxis plans to expand its business through its recent acquisition of BiOptix Diagnostics, a medical device company.

Venaxis has acquired approximately 98% of BiOptix’s voting shares for 14% of the former’s post-deal outstanding common shares.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

"The transaction will enable Horizon Pharma to expand its presence into European and other international markets."

M Pharmaceutical announced to expand its business into women’s health market by acquiring an undisclosed company with an FDA-approved product.

The acquirer is a clinical-stage company that develops technologies for obesity and weight management, whereas the target company is a private pharmaceutical company.

Horizon Pharma has entered a definitive agreement to acquire all outstanding and issued shares of Raptor Pharmaceutical for a purchase consideration of $800m, which is expected to be completed in November.

The transaction will enable Horizon Pharma to expand its presence into European and other international markets, strengthen its business revenue across orphan, rheumatology and primary care, and focus on rare diseases.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now